Cyclacel Pharmaceuticals Files 8-K on June 30, 2025
Ticker: BGMSP · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1130166
Sentiment: neutral
Topics: corporate-filing, financial-reporting
Related Tickers: CYCC
TL;DR
Cyclacel filed an 8-K on 6/30/25 covering votes and financials.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an 8-K on June 30, 2025, reporting on matters submitted to a vote of security holders and including financial statements and exhibits. The filing details the company's corporate structure and its fiscal year end of December 31st. No specific financial figures or vote outcomes were detailed in the provided excerpt.
Why It Matters
This filing indicates ongoing corporate activities and reporting requirements for Cyclacel Pharmaceuticals, Inc., providing transparency to investors regarding company matters and financial reporting.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative news or significant financial events.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- June 30, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- December 31st (date) — Fiscal Year End
FAQ
What specific matters were submitted to a vote of security holders?
The provided excerpt does not specify the exact matters submitted to a vote of security holders, only that this was a subject of the 8-K filing.
What financial statements are included in this filing?
The excerpt states that financial statements are included, but does not detail their content or specific figures.
When is Cyclacel Pharmaceuticals, Inc.'s fiscal year end?
Cyclacel Pharmaceuticals, Inc.'s fiscal year end is December 31st.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the accession number for this filing?
The accession number for this filing is 0001641172-25-017152.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).